Publications by authors named "J K Wasman"
Article Synopsis
- Researchers tested a new medicine called Pc 4 to see if it can help treat certain throat problems by injecting it directly into mouth and throat tissue in rabbits.
- The rabbits had no major reactions or problems after getting the injections, which is a good sign.
- The study showed that injecting Pc 4 into the tissues seemed safe, with only slight signs of irritation that weren't serious.
There is an unmet clinical need for a non-invasive and cost-effective test for oral squamous cell carcinoma (OSCC) that informs clinicians when a biopsy is warranted. Human beta-defensin 3 (hBD-3), an epithelial cell-derived anti-microbial peptide, is pro-tumorigenic and overexpressed in early-stage OSCC compared to hBD-2. We validate this expression dichotomy in carcinoma in situ and OSCC lesions using immunofluorescence microscopy and flow cytometry.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the biological differences in HPV-associated oropharyngeal cancer between Black and White patients to enhance prognostic accuracy and treatment personalization.
- The multinucleation index (MuNI) was used to measure the concentration of multinucleated tumor cells in both groups, revealing significant differences: Black patients had a higher MuNI score than White patients.
- The findings indicate that while the established MuNI cutoff is prognostic for White patients, it does not effectively stratify risk for Black patients, highlighting the need for tailored biomarkers in cancer treatment.
Treatment failure patterns are similar between p16- and p16+ oropharyngeal squamous cell carcinomas.
Laryngoscope Investig Otolaryngol
August 2022
Background: The incidence of p16+ oropharyngeal squamous cell carcinoma (OPSCC) has been increasing. The notion that p16+ OPSCC has a propensity for atypical and disseminating metastasis has gained traction. We compared treatment failure patterns in p16+ and p16- OPSCC and evaluated survival impact.
View Article and Find Full Text PDFAmeloblastoma is a benign, locally aggressive odontogenic neoplasm with variable solid and cystic morphology. On account of its histologic variety, diagnostically challenging cases can bear resemblance to odontogenic keratocyst/keratocystic odontogenic tumor (KCOT) or dentigerous cyst (DC). BRAF mutation has been reported to be specific for and frequent in ameloblastoma, and this study evaluated the usefulness of immunohistochemistry (IHC) using the BRAF VE1 mutant-specific antibody as a diagnostic adjunct in this setting.
View Article and Find Full Text PDF